Get started
222

DAWNRAYS PHARMACEUTICAL HLDGS

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

2348 chart


Full chart

2348 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.86 B‬HKD
Dividend yield (indicated)
6.45%
Price to earnings Ratio (TTM)
3.05
Basic EPS (TTM)
0.41HKD
Net income (FY)
‪360.23 M‬HKD
Revenue (FY)
‪1.27 B‬HKD
Shares float
‪593.50 M‬
Beta (1Y)
0.31

Employees


Employees (FY)
‪1.14 K‬
Change (1Y)
+37 +3.35%
Revenue / Employee (1Y)
‪142.48 K‬HKD
Net income / Employee (1Y)
‪40.35 K‬HKD

About DAWNRAYS PHARMACEUTICAL HLDGS


Sector
Health Technology
CEO
Li Wei Yu
Headquarters
Hong Kong
Website
en.dawnrays.com
Founded
1995
FIGI
BBG000FMB261
Dawnrays Pharmaceutical Holdings Ltd. operates as an investment holding company, which engages in the development, manufacturing and selling of cephalosporin antibiotics, and various system specific medicines. It operates through the following business segments: Intermediates & Bulk Medicines, and Finished Drugs. The Intermediates & Bulk Medicines segment engages in the manufacturing and selling of intermediates and bulk medicines. The Finished Drugs segment engages in the manufacturing and selling of antibiotics finished drugs and non-antibiotics finished drugs. The company was founded on December 8, 1995 and is headquartered in Hong Kong.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

2348 news



Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 2348 is 1.28 HKD — it has increased by 7.26% in the past 24 hours. Watch DAWNRAYS PHARMACEUTICAL HLDGS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange DAWNRAYS PHARMACEUTICAL HLDGS stocks are traded under the ticker 2348.
2348 stock has risen by 6.40% compared to the previous week, the month change is a 7.26% rise, over the last year DAWNRAYS PHARMACEUTICAL HLDGS has showed a 17.43% increase.
2348 reached its all-time high on Oct 22, 2014 with the price of 4.07 HKD, and its all-time low was 0.22 HKD and was reached on Jun 15, 2005. View more price dynamics on 2348 chart.
See other stocks reaching their highest and lowest prices.
2348 stock is 3.91% volatile and has beta coefficient of 0.31. Track DAWNRAYS PHARMACEUTICAL HLDGS stock price on the chart and check out the list of the most volatile stocks — is DAWNRAYS PHARMACEUTICAL HLDGS there?
Today DAWNRAYS PHARMACEUTICAL HLDGS has the market capitalization of ‪1.86 B‬, it has increased by 0.80% over the last week.
Yes, you can track DAWNRAYS PHARMACEUTICAL HLDGS financials in yearly and quarterly reports right on TradingView.
DAWNRAYS PHARMACEUTICAL HLDGS is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
2348 net income for the last half-year is ‪534.28 M‬ HKD, while the previous report showed ‪75.69 M‬ HKD of net income which accounts for 605.90% change. Track more DAWNRAYS PHARMACEUTICAL HLDGS financial stats to get the full picture.
DAWNRAYS PHARMACEUTICAL HLDGS dividend yield was 7.62% in 2023, and payout ratio reached 33.31%. The year before the numbers were 6.62% and 31.67% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 5, 2024, the company has ‪1.14 K‬ employees. See our rating of the largest employees — is DAWNRAYS PHARMACEUTICAL HLDGS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DAWNRAYS PHARMACEUTICAL HLDGS EBITDA is ‪340.92 M‬ HKD, and current EBITDA margin is 31.35%. See more stats in DAWNRAYS PHARMACEUTICAL HLDGS financial statements.
Like other stocks, 2348 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DAWNRAYS PHARMACEUTICAL HLDGS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DAWNRAYS PHARMACEUTICAL HLDGS technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DAWNRAYS PHARMACEUTICAL HLDGS stock shows the neutral signal. See more of DAWNRAYS PHARMACEUTICAL HLDGS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.